Everything below concerns reference standard. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
== Other uses == Operation Snowcap (1987-1994) a U.S. counter-narcotics trafficking program Snowcaps (song), a 1999 song by Unwed Sailor Snow Cap (story) by Matthew S. Armstrong from the graphic novel anthology Flight, see List of volumes of Flight
In 2015, Rachel reunites with Yoshi and they spend the night together catching up and later looking for his missing backpack. When asked about her falling out with Shira, Rachel, while looking a bit guilty, hastily says it was just teen stuff, but that Shira got mad for "no reason". She and Yoshi wind up ending their night in a make out session, which causes Yoshi to ejaculate and ruin his sperm sample for Kendra’s IVF treatment, and when Shira finds out Baby caused him to do so she becomes even more hurt and angry and cements her decision to use an anonymous donor. Danny Burstein as Uncle Barry, Naomi's boisterous, obnoxious uncle by marriage with her aunt Sylvia, the sister of Naomi's mother. Avia Fields as Walter and Benjamin Hooper-Schwooper, the hyperactive twin sons of Kendra and Shira, born in 2015 or 2016. Julie Klausner as Carol Schwartz, one of Naomi's older sisters. Zoe Lister-Jones as Susan Schwartz, one of Naomi's older sisters.
(2026) make the name of the toxodontid Andinotoxodon bolivarensis, originally described in a doctoral dissertation, available under the International Code of Zoological Nomenclature. The first confirmed fossil material of Late Pleistocene Toxodon platensis from the San Luis Province (Argentina), providing information on the intracranial anatomy of members of this species, is described from the Barranquita Formation by Hernández Del Pino et al. (2026). Evidence from the study of tooth wear of Tremacyllus and Paedotherium, interpreted as indicating that pachyrukhine hegetotheriid notoungulates were mainly fruit-seed consumers rather than grazers, is presented by Armella & Croft (2026). A study on the evolution of the morphological similarity to molar teeth in premolar teeth of ungulates, based on data from extant and extinct artiodactyls and perissodactyls, is published by Ashbaugh, Jamniczky & Theodor (2026). A study on tooth wear of early Pleistocene ungulates from the Quibas site (Murcia, Spain), interpreted as indicative of a broad spectrum of feeding behaviours consistent with presence of mosaic environments including grasslands with wooded patches, is published by Ramírez-Pedraza, Agustí & Piñero (2026). Hussain et al. (2026) reconstruct the dietary presences of Pleistocene ungulates from the Pinjor Formation (Pakistan) on the basis of the study of their tooth wear, interpreted as indicating that the studied assemblage was dominated by grazers but also included browsers and mixed-feeders.
Sources: en.wikipedia.org
== Overview == The series focuses on Olivia Pope and her crisis management firm, Olivia Pope & Associates, and its staff, as well as staff at the White House in Washington D.C. as political scandals occur and they must try to deal with them.
June 6, 2000: Law in favor of equal access for women and men to electoral mandates and elective functions. June 30, 2000: Law concerning compensatory allowance in divorce matters. July 10, 2000: Law concerning the election of senators, with measures regarding gender parity. November 28, 2000: Government amendment lifting the ban on night work for women, against the opinion of the French Communist Party (PCF), which wanted to ban night work for all, except for exemptions. December 23, 2000: Social Security Financing Law for 2001, which includes the creation of a parental presence allowance in case of illness, accident, or disability of the child. May 9, 2001: Law concerning professional equality between women and men. November 16, 2001: Law concerning the fight against discrimination. December 3, 2001: Law concerning the rights of the surviving spouse and illegitimate children, and modernizing various provisions of inheritance law. December 21, 2001: Social Security Financing Act for 2002, which notably includes the establishment of paternity leave. December 21, 2001: Decree establishing a National Commission against Violence towards Women. January 9, 2002: Decree regarding the provision of emergency contraception medication to minors. January 17, 2002: Social Modernization Act, which notably includes elements related to sexual harassment, as well as others concerning discrimination in housing. January 22, 2002: Law concerning access to origins for adopted individuals and wards of the state.
Following the re-election of Donald Trump in November 2024, Lula congratuled Trump on X (formerly Twitter) and again, after his inauguration, in January 2025, when Lula also highlighted Brazil-United States historical friendship. After Trump first threatened to impose tariffs on steel and aluminium in February 2025, and fulfilled that in March, Lula warned the United States economy could self-inflict damage, and promised to open a complaint against the 25% tariffs imposed on Brazilian steel and aluminum exports bound to US at the World Trade Organization. He also said he would not hesitate to call Trump to disscuss such tariffs, and hoped he answered his call.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.